Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axsome Thera
(NQ:
AXSM
)
84.85
+2.71 (+3.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axsome Thera
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says
January 25, 2024
Axsome Therapeutics' growth potential with RBC Capital's optimistic coverage. Auvelity's rapid Rx growth projects sales of $296M in 2024, outperforming estimates.
Via
Benzinga
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
January 23, 2024
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
January 23, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
The Analyst Landscape: 6 Takes On Axsome Therapeutics
January 16, 2024
Via
Benzinga
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
January 04, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Analyst Expectations for Axsome Therapeutics's Future
November 07, 2023
Via
Benzinga
Earnings Scheduled For November 6, 2023
November 06, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via
Benzinga
3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years
January 03, 2024
Is it too late to invest in these fast-growing stocks?
Via
The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
January 02, 2024
The types of innovative drugs these companies develop are always in high demand.
Via
The Motley Fool
Prediction: These 3 Stocks Will Soar in 2024
January 01, 2024
Investors could enjoy an especially happy new year with these great stocks.
Via
The Motley Fool
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
December 11, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 Unstoppable Stocks to Buy Right Now
December 10, 2023
These stocks could be just the ticket for investors seeking strong growth.
Via
The Motley Fool
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
December 07, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
November 27, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
AXSM FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
November 25, 2023
WHY: NEW YORK, NY - (NewMediaWire) - November 25, 2023 - Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. (“Axsome”) (NASDAQ: AXSM)...
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
November 24, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
November 22, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 Biotech Stocks That Could Be Millionaire Makers
November 22, 2023
Many biotech stocks offer exciting long-term growth prospects.
Via
The Motley Fool
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
November 21, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
November 18, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
November 17, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers – AXSM
November 16, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
3 Growth Stocks to Buy Right Now Without Any Hesitation
November 11, 2023
Investors shouldn't have to deliberate for too long about these great stocks.
Via
The Motley Fool
3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates
November 09, 2023
Can these promising growth stocks continue rising in value?
Via
The Motley Fool
Topics
Economy
Exposures
Interest Rates
Axsome's Strategy on Payer Coverage Slowly Pays Off, Depression Drug Sales Show Growth
November 06, 2023
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q3 revenues of $57.8 million, up 244% Y/Y, beating the consensus of $54.75 m
Via
Benzinga
Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript
November 06, 2023
AXSM earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
November 02, 2023
Axsome’s headquarters to be lit in teal as part of the Alzheimer’s Foundation of America awareness campaign
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at Upcoming Investor Conferences
October 31, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.